- Home
- PBT vs AUTL Comparison
PBT vs AUTL Comparison
Compare PBT & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBT | AUTL |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 596.2M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | PBT | AUTL |
|---|---|---|
| Price | $33.03 | $2.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 88.0K | ★ 1.4M |
| Earning Date | 03-13-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | N/A | $53.96 |
| P/E Ratio | $57.37 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $16.25 | $1.18 |
| 52 Week High | $37.00 | $2.58 |
Technical Indicators
Market Signals| Indicator | PBT | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 46.52 | 46.33 |
| Support Level | $32.75 | $1.37 |
| Resistance Level | $35.46 | $2.07 |
| Average True Range (ATR) | 0.97 | 0.09 |
| MACD | -0.33 | -0.03 |
| Stochastic Oscillator | 29.60 | 27.78 |
Price Performance
Historical ComparisonAbout PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole, and others across Texas. The company earns the majority of its revenue in the form of royalties received through its properties.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.